Published in Exp Ther Med on January 20, 2017
Parkinson's disease. Lancet (2004) 3.08
Parkinson's disease: genetics and pathogenesis. Annu Rev Pathol (2011) 2.39
Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury. Stem Cells (2004) 2.12
Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet (2001) 1.96
Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev (2011) 1.90
Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci (2008) 1.81
Animal models of PD: pieces of the same puzzle? Neuron (2002) 1.34
Parkinson's disease dementia and dementia with Lewy bodies: different aspects of one entity. Int Psychogeriatr (2009) 1.26
Prevalence, incidence, and mortality of PD: a door-to-door survey in Ilan county, Taiwan. Neurology (2001) 1.14
Mesenchymal stem cell transplantation attenuates blood brain barrier damage and neuroinflammation and protects dopaminergic neurons against MPTP toxicity in the substantia nigra in a model of Parkinson's disease. J Neuroimmunol (2009) 1.11
Progress in Parkinson's disease-where do we stand? Prog Neurobiol (2008) 1.10
Evaluation of animal models of Parkinson's disease for neuroprotective strategies. J Neurosci Methods (2004) 1.08
Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat. Cell Transplant (2009) 1.05
The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. Ther Deliv (2014) 1.03
Pathological Interface Between Oligomeric Alpha-Synuclein and Tau in Synucleinopathies. Biol Psychiatry (2015) 0.98
Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiol Dis (2005) 0.98
Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains. Behav Brain Res (2005) 0.95
The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects. Fluids Barriers CNS (2013) 0.95
The cellular repair of the brain in Parkinson's disease--past, present and future. Transpl Immunol (2004) 0.89
Intranasal delivery of stem cells to the brain. Expert Opin Drug Deliv (2011) 0.89
Noninvasive near-infrared live imaging of human adult mesenchymal stem cells transplanted in a rodent model of Parkinson's disease. Int J Nanomedicine (2012) 0.86
Emerging Insights for Translational Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Studies: Towards Prediction of Nose-to-Brain Transport in Humans. AAPS J (2015) 0.85
The search for a curative cell therapy in Parkinson's disease. J Neurol Sci (2007) 0.82
Increasing the Efficiency of Parkinson's Disease Treatment Using a poly(lactic-co-glycolic acid) (PLGA) Based L-DOPA Delivery System. Exp Neurobiol (2014) 0.82
Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of Alzheimer's and Parkinson's disease. Cell Transplant (2014) 0.82
Effects of serotoninergic drugs on tremor induced by physostigmine in rats. Behav Brain Res (2000) 0.80
Cell transplantation for patients with Parkinson's disease. Handb Exp Pharmacol (2006) 0.78
Transplantation of mouse embryonic stem cell-derived neurons into the striatum, subthalamic nucleus and substantia nigra, and behavioral recovery in hemiparkinsonian rats. Neurosci Lett (2005) 0.77